Volume 131, Issue 22



May 31, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Circulating tumor DNA for assessment of classical Hodgkin lymphoma.
See the article by Spina et al.

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma
Two papers in this issue concentrate on the molecular landscape of classical Hodgkin lymphoma (cHL). In a plenary paper, Spina and colleagues demonstrate that circulating tumor DNA (ctDNA) can be used to assess the genetics of cHL and to track residual disease. Tiacci et al use microdissection and single-cell sequencing to establish the importance of JAK-STAT pathway genes in cHL, an observation that is mirrored in Spina’s ctDNA study.

Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study
Cottereau et al focus on earlier identification of patients with follicular lymphoma at highest risk of relapse. They demonstrate that combining positron emission tomography (PET) assessments of tumor burden at presentation and at end of induction therapy better predicts prognosis.

Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation
Zhu and colleagues perform exome-wide association studies that identify rare variants that predict survival following HLA-matched unrelated stem cell transplantation.

The role of JAK2 inhibitors in MPNs 7 years after approval
Passamonti and Maffioli review the positive impact of JAK2 inhibitors on myeloproliferative neoplasm (MPN) therapy 7 years after approval and the challenges of addressing treatment failure in polycythemia, while emphasizing the challenge of addressing treatment failure.

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML
Cucchi et al examine the impact of the FLT3-ITD allelic ratio on prognosis in pediatric acute myeloid leukemia (AML), demonstrating that an RNA allelic ratio of >0.5 predicts outcome and response to the selective FLT3-kinase inhibitor gilteritinib.

14-3-3 proteins in platelet biology and glycoprotein Ib-IX signaling
14-3-3 proteins all bind serine/threonine–based peptide motifs in a phosphorylation-dependent manner. Chen et al review the role of 14-3-3 proteins in platelets, where it binds glycoprotein Ib-IX, regulating binding to von Willebrand factor and modulating downstream signal transduction.


View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.